Traditional Chinese Medicine Decoctions Significantly Reduce the Mortality in Severe and Critically Ill Patients with COVID-19: A Retrospective Cohort Study
| Autor: | Xiaodong Huang, Bo Jiang, Suping Lang, Ping Xie, Xuedong An, Meng Luo, An Fan, Qian Yang, Jiaxing Tian, Qin-Guo Sun, Xiuyang Li, Xiaolin Tong, Liyun Duan, Fengmei Lian, Sheng-Hui Zhao, Pengcheng Luo, Ping Liu |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
0301 basic medicine
Male medicine.medical_specialty Critical Illness Traditional Chinese medicine Logistic regression Severity of Illness Index Odds 03 medical and health sciences 0302 clinical medicine Internal medicine Severity of illness medicine Humans Medicine Chinese Traditional Aged Retrospective Studies business.industry COVID-19 Retrospective cohort study General Medicine Odds ratio Middle Aged COVID-19 Drug Treatment 030104 developmental biology Complementary and alternative medicine 030220 oncology & carcinogenesis Cohort Propensity score matching Female business Drugs Chinese Herbal |
| Zdroj: | The American journal of Chinese medicine. 49(5) |
| ISSN: | 1793-6853 |
| Popis: | Coronavirus disease (COVID-19) is a new infectious disease associated with high mortality, and traditional Chinese medicine decoctions (TCMDs) have been widely used for the treatment of patients with COVID-19 in China; however, the impact of these decoctions on severe and critical COVID-19-related mortality has not been evaluated. Therefore, we aimed to address this gap. In this retrospective cohort study, we included inpatients diagnosed with severe/critical COVID-19 at the Tongren Hospital of Wuhan University and grouped them depending on the recipience of TCMDs (TCMD and non-TCMD groups). We conducted a propensity score-matched analysis to adjust the imbalanced variables and treatments and used logistic regression methods to explore the risk factors associated with in-hospital death. Among 282 patients with COVID-19 who were discharged or died, 186 patients (66.0%) received TCMD treatment (TCMD cohort) and 96 (34.0%) did not (non-TCMD cohort). After propensity score matching at a 1:1 ratio, 94 TCMD users were matched to 94 non-users, and there were no significant differences in baseline clinical variables between the two groups of patients. The all-cause mortality was significantly lower in the TCMD group than in the non-TCMD group, and this trend remained valid even after matching (21.3% [20/94] vs. 39.4% [37/94]). Multivariable logistic regression model showed that disease severity (odds ratio: 0.010; 95% CI: 0.003, 0.037; [Formula: see text]¡ 0.001) was associated with increased odds of death and that TCMD treatment significantly decreased the odds of in-hospital death (odds ratio: 0.115; 95% CI: 0.035, 0.383; [Formula: see text]¡ 0.001), which was related to the duration of TCMD treatment. Our findings show that TCMD treatment may reduce the mortality in patients with severe/critical COVID-19. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|